NCT00229684 - ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Tesaglitazar

2 mg once daily in oral form

DRUG

pioglitazone

45 mg once daily in oral form

Trial Locations (21)

Research Site, Pasadena

Research Site, Washington D.C.

Research Site, Gainesville

Research Site, Miami

Research Site, Orlando

Research Site, Augusta

Research Site, Columbus

Research Site, New Orleans

Research Site, Reno

Research Site, Flushing

Research Site, Durham

Research Site, Cleveland

Research Site, Columbus

Research Site, Tulsa

Research Site, Cheswick

Research Site, Philadelphia

Research Site, Nashville

Research Site, Midland

Research Site, San Antonio

Research Site, Gig Harbor

Research Site, Seattle